Developer docs
API playgroundTry for free, no card

Search company profiles

BioAdvance

Full company profile

uuid0000dnn

Namestring
BioAdvance
Legal namestring
BioAdvance
Websiteurl
bioadvance.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

BioAdvance is a Pennsylvania-based evergreen venture capital fund that provides seed and Series A funding to early-stage life science companies headquartered in the Mid-Atlantic U.S. I-95 corridor (Pennsylvania, New Jersey, Delaware, Maryland, Washington DC, and parts of New York and Virginia). Founded in 2002, the fund has invested in 120+ companies across five sector tracks: Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. Initial investment sizes typically range from $500,000 to $1,500,000, with the ability to commit up to $5,000,000 over a portfolio company's lifecycle. The fund reports 28 exits, 12 FDA-approved products, and over $4.4 billion in follow-on capital attracted by portfolio companies from third-party investors.

BioAdvance's investment model is differentiated by its evergreen fund structure (perpetual life, no fixed fund-end), which allows it to hold positions for the full 10-15+ year arc of life science development without forced exits. The fund's competitive position rests on its regional mandate and dominance in the Mid-Atlantic corridor, where locally headquartered life science VCs are scarce relative to Boston and San Francisco. The team of approximately 12 (7 staff plus 5 advisors/EIRs) combines operating leadership from major pharma/medtech (Kodak, Siemens, J&J, Amgen, Merck, GSK, Pfizer) with academic and policy ties (University of Pennsylvania, Princeton, PA Department of Community & Economic Development), enabling both sector diligence and syndication across 8VC, DCVC Bio, Modi Ventures, and others.

The fund's economic model relies on capital appreciation from portfolio exits (28 realized to date), supported by capital-efficient investment philosophy and strong co-investor syndication. BioAdvance does not develop proprietary technology; its "product" is capital deployment plus operational support, board participation, and follow-on investor introductions. Notable active portfolio companies include Latus Bio (AAV gene therapy), ImmunoGenesis (immuno-oncology), Wellsheet (clinical workflow, acquired by Elsevier in 2026), Strados Labs (respiratory monitoring), and KaloCyte (synthetic blood substitute).

Short descriptiontext

BioAdvance is a Pennsylvania-based evergreen venture capital fund providing $500K-$1.5M seed and Series A investments to early-stage life science companies in the Mid-Atlantic U.S. I-95 corridor, with 120+ portfolio companies across therapeutics, devices, digital health, diagnostics, and research tools.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science venture capital, seed stage investing, biotech startup funding, evergreen investment fund, early-stage healthcare investing
Product category
Life Sciences Venture Capital
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Investment returns from portfolio exits (evergreen fund model)
bioadvance.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Initial seed / Series A investment
ModelOtherBilling cadenceMulti-year contract
Notes

Initial investment size typically $500,000 to $1,500,000; ability to commit up to $5,000,000 over the lifecycle of a company. BioAdvance can lead rounds between $500,000 and $5,000,000 and frequently co-invests with other VCs. Investment terms are not publicly disclosed (negotiated bilaterally per company).

bioadvance.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioAdvance is a privately held, evergreen venture capital fund that invests $500,000–$1,500,000 in seed and Series A rounds (with reserves up to $5,000,000 per company over its lifecycle) in early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor from NYC to DC). The fund deploys capital across five sector tracks — Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools — and provides operational support, board participation, and introductions to follow-on investors alongside its core equity investment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 120+ companies invested in since inception
+5 more records
Product overview1 text field

BioAdvance Capital is a single, unified evergreen venture capital fund (not a multi-product SaaS platform) that provides seed and Series A funding to early-stage life science companies. The fund is structured around a single core investment service (the seed/Series A investment program) that is deployed across five distinct sector tracks: Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. BioAdvance does not sell these as separate products; rather, they represent the five sector verticals in which the fund actively invests. Across these verticals, the firm has backed 120+ portfolio companies that together have attracted over $4.4 billion in follow-on external capital, and the fund itself has committed over $50 million to almost 100 seed-stage companies during Barbara Schilberg's tenure as CEO (2002-2021). Notable active portfolio companies include Latus Bio (AAV gene therapy), Ladder Bio (Spiroligomer platform), ImmunoGenesis (immunotherapy), Wellsheet (AI clinical workflows), and KaloCyte (synthetic blood substitute).

Product and service6 records
1Seed-Stage Life Sciences Investment Program
CategoryCore investment service
Description

Core equity investment program providing seed and Series A funding (initial checks of $500,000–$1,500,000, up to $5,000,000 over a company's lifecycle) to early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor between NYC and Washington, D.C.). Designed to help companies reach critical de-risking or value-inflection milestones.

2Therapeutics Investment Track
CategoryInvestment sector focus
Description

Sector-specific investment track for therapeutic innovations including novel small molecules, gene therapies (e.g., AAV-based platforms), antibodies, and cell therapies addressing significant unmet needs in human health.

3Medical Devices Investment Track
CategoryInvestment sector focus
Description

Sector-specific investment track for medical device companies developing novel hardware, diagnostics devices, and procedural technologies for the healthcare market.

4Digital Health Investment Track
CategoryInvestment sector focus
Description

Sector-specific investment track for digital health companies with proven product-market-fit and established market traction as demonstrated by a growing revenue stream. Includes AI clinical workflow, SaaS, and clinician retention intelligence platforms.

5Diagnostics Investment Track
CategoryInvestment sector focus
Description

Sector-specific investment track for diagnostics companies developing novel testing platforms, rapid assay-based (RQA) products, point-of-care diagnostics, and imaging agents.

6Research Tools Investment Track
CategoryInvestment sector focus
Description

Sector-specific investment track for research tools companies that provide enabling technologies, platforms, and consumables for academic and pharmaceutical research and drug discovery.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierStrategic Ecosystem PartnerTypeStrategic or Co-development Partner
Description

The Dean of the University of Pennsylvania School of Medicine and EVP of the Health System (Jonathan Epstein, M.D.) serves on the BioAdvance Board of Directors, reflecting a strategic relationship with Penn Medicine — a key source of translational research and spinout deal flow for BioAdvance in the Philadelphia region.

Strategic tierStrategic Ecosystem PartnerTypeOthers
Description

The Deputy Secretary of the PA DCED Office of Technology & Entrepreneurship (Jen Gilburg) serves on the BioAdvance Board of Directors, evidencing a close relationship with the Commonwealth of Pennsylvania's technology and life science economic-development apparatus. The Commonwealth has historically supported BioAdvance's evergreen fund structure through state allocations.

Strategic tierEcosystem PartnerTypeStrategic or Co-development Partner
Description

BioAdvance CEO Shahram Hejazi is a lecturer at Princeton University's School of Engineering, providing BioAdvance with a direct line into Princeton's translational research and student/faculty entrepreneurship pipeline in the Mid-Atlantic.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pennsylvania-based, state-affiliated seed and early-stage investor focused on technology and life sciences. Closest analog to BioAdvance in mission, regional mandate, evergreen orientation, and stage focus; co-invests with BioAdvance in multiple portfolio companies (e.g., Latus Bio).

TypeDirect peer
Description

Boston-based early-stage life sciences venture fund focused on cardiovascular and CNS therapeutics. Directly comparable in stage (seed/Series A), sector focus, and evergreen/patient-capital orientation; Rick Jones of BioAdvance's team previously served as a Director there.

3BioEnterprise
TypeRegional player
Description

Midwest (Cleveland) regional life science commercialization organization and investor in therapeutics, medical devices, and diagnostics. Comparable as a regional life science investor focused on company formation and seed-stage capital, though operating in a different geography.

TypeRegional player
Description

Pennsylvania-focused life science seed fund with a similar mission of supporting early-stage companies within the state. Comparable regional mandate and stage focus, though narrower geographic scope within PA.

TypeBroad incumbent
Description

Hospital-system-affiliated venture arm investing in therapeutics, medtech, and digital health. Comparable in sector focus and mission-driven orientation, though anchored to a single health system and broader portfolio scope than BioAdvance.

TypeBroad incumbent
Description

Large, established life science venture firm investing across stages from formation to public company. Operates broadly in BioAdvance's core therapeutic verticals but at much larger check sizes and without a regional mandate.

TypeBroad incumbent
Description

Boston-based early-stage life sciences venture firm with a similar focus on building biotechs from inception. Comparable in stage and therapeutic orientation, but operates nationally and globally with substantially more capital.

TypeRegional player
Description

Philadelphia-area angel investing group that focuses on early-stage companies in the Mid-Atlantic. Gregory Harriman of BioAdvance is a member; comparable in regional focus and stage, though broader sector mandate.

TypeEmerging player
Description

Hospital-affiliated accelerator investing in early-stage health technology and digital health companies. Comparable in seed-stage health-tech orientation and ecosystem-driven model, though focused on a single health system in Los Angeles.

TypeBroad incumbent
Description

One of the largest U.S. venture firms with a dedicated healthcare practice investing across therapeutics, medical devices, and digital health at all stages. Operates broadly in BioAdvance's core verticals and increasingly at seed/Series A where BioAdvance competes.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment190 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioAdvance

Life Sciences Venture Capitalbioadvance.com

BioAdvance is a Pennsylvania-based evergreen venture capital fund providing $500K-$1.5M seed and Series A investments to early-stage life science companies in the Mid-Atlantic U.S. I-95 corridor, with 120+ portfolio companies across therapeutics, devices, digital health, diagnostics, and research tools.

What BioAdvance does

BioAdvance is a Pennsylvania-based evergreen venture capital fund that provides seed and Series A funding to early-stage life science companies headquartered in the Mid-Atlantic U.S. I-95 corridor (Pennsylvania, New Jersey, Delaware, Maryland, Washington DC, and parts of New York and Virginia). Founded in 2002, the fund has invested in 120+ companies across five sector tracks: Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. Initial investment sizes typically range from $500,000 to $1,500,000, with the ability to commit up to $5,000,000 over a portfolio company's lifecycle. The fund reports 28 exits, 12 FDA-approved products, and over $4.4 billion in follow-on capital attracted by portfolio companies from third-party investors.

BioAdvance's investment model is differentiated by its evergreen fund structure (perpetual life, no fixed fund-end), which allows it to hold positions for the full 10-15+ year arc of life science development without forced exits. The fund's competitive position rests on its regional mandate and dominance in the Mid-Atlantic corridor, where locally headquartered life science VCs are scarce relative to Boston and San Francisco. The team of approximately 12 (7 staff plus 5 advisors/EIRs) combines operating leadership from major pharma/medtech (Kodak, Siemens, J&J, Amgen, Merck, GSK, Pfizer) with academic and policy ties (University of Pennsylvania, Princeton, PA Department of Community & Economic Development), enabling both sector diligence and syndication across 8VC, DCVC Bio, Modi Ventures, and others.

The fund's economic model relies on capital appreciation from portfolio exits (28 realized to date), supported by capital-efficient investment philosophy and strong co-investor syndication. BioAdvance does not develop proprietary technology; its "product" is capital deployment plus operational support, board participation, and follow-on investor introductions. Notable active portfolio companies include Latus Bio (AAV gene therapy), ImmunoGenesis (immuno-oncology), Wellsheet (clinical workflow, acquired by Elsevier in 2026), Strados Labs (respiratory monitoring), and KaloCyte (synthetic blood substitute).

BioAdvance firmographics

Firmographics
Name
BioAdvance
Legal name
BioAdvance
Website
https://bioadvance.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
51–100 employees
Short description
BioAdvance is a Pennsylvania-based evergreen venture capital fund providing $500K-$1.5M seed and Series A investments to early-stage life science companies in the Mid-Atlantic U.S. I-95 corridor, with 120+ portfolio companies across therapeutics, devices, digital health, diagnostics, and research tools.
Ownership category
akta.pro rank

Where BioAdvance is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioAdvance business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

  1. Investment returns from portfolio exits (evergreen fund model):

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInitial seed / Series A investment

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

BioAdvance product offering

Product offering

Core offering

BioAdvance is a privately held, evergreen venture capital fund that invests $500,000–$1,500,000 in seed and Series A rounds (with reserves up to $5,000,000 per company over its lifecycle) in early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor from NYC to DC). The fund deploys capital across five sector tracks — Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools — and provides operational support, board participation, and introductions to follow-on investors alongside its core equity investment.

Product overview

BioAdvance Capital is a single, unified evergreen venture capital fund (not a multi-product SaaS platform) that provides seed and Series A funding to early-stage life science companies. The fund is structured around a single core investment service (the seed/Series A investment program) that is deployed across five distinct sector tracks: Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools. BioAdvance does not sell these as separate products; rather, they represent the five sector verticals in which the fund actively invests. Across these verticals, the firm has backed 120+ portfolio companies that together have attracted over $4.4 billion in follow-on external capital, and the fund itself has committed over $50 million to almost 100 seed-stage companies during Barbara Schilberg's tenure as CEO (2002-2021). Notable active portfolio companies include Latus Bio (AAV gene therapy), Ladder Bio (Spiroligomer platform), ImmunoGenesis (immunotherapy), Wellsheet (AI clinical workflows), and KaloCyte (synthetic blood substitute).

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed-Stage Life Sciences Investment Program Core equity investment program providing seed and Series A funding (initial checks of $500,000–$1,500,000, up to $5,000,000 over a company's lifecycle) to early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor between NYC and Washington, D.C.). Designed to help companies reach critical de-risking or value-inflection milestones.
  • Therapeutics Investment Track Sector-specific investment track for therapeutic innovations including novel small molecules, gene therapies (e.g., AAV-based platforms), antibodies, and cell therapies addressing significant unmet needs in human health.
  • Medical Devices Investment Track Sector-specific investment track for medical device companies developing novel hardware, diagnostics devices, and procedural technologies for the healthcare market.
  • Digital Health Investment Track Sector-specific investment track for digital health companies with proven product-market-fit and established market traction as demonstrated by a growing revenue stream. Includes AI clinical workflow, SaaS, and clinician retention intelligence platforms.
  • Diagnostics Investment Track Sector-specific investment track for diagnostics companies developing novel testing platforms, rapid assay-based (RQA) products, point-of-care diagnostics, and imaging agents.
  • Research Tools Investment Track Sector-specific investment track for research tools companies that provide enabling technologies, platforms, and consumables for academic and pharmaceutical research and drug discovery.

Quantifiable outcome

  • 120+ companies invested in since inception
  • +5 more outcomes

Companies that use BioAdvance

Customer profile

Named customers13 records

Segments6 records

Ideal customer profiles4 records

BioAdvance technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioAdvance partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic ecosystem partner and ecosystem partner.

  • University of Pennsylvania (Penn Medicine)strategic ecosystem partnerStrategic or Co-development PartnerThe Dean of the University of Pennsylvania School of Medicine and EVP of the Health System (Jonathan Epstein, M.D.) serves on the BioAdvance Board of Directors, reflecting a strategic relationship with Penn Medicine — a key source of translational research and spinout deal flow for BioAdvance in the Philadelphia region.
  • Pennsylvania Department of Community & Economic Development (DCED), Office of Technology & Entrepreneurshipstrategic ecosystem partnerOthersThe Deputy Secretary of the PA DCED Office of Technology & Entrepreneurship (Jen Gilburg) serves on the BioAdvance Board of Directors, evidencing a close relationship with the Commonwealth of Pennsylvania's technology and life science economic-development apparatus. The Commonwealth has historically supported BioAdvance's evergreen fund structure through state allocations.
  • Princeton Universityecosystem partnerStrategic or Co-development PartnerBioAdvance CEO Shahram Hejazi is a lecturer at Princeton University's School of Engineering, providing BioAdvance with a direct line into Princeton's translational research and student/faculty entrepreneurship pipeline in the Mid-Atlantic.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

BioAdvance competitors and assessment

Company assessment

Direct peers

  • Ben Franklin Technology Partners: Pennsylvania-based, state-affiliated seed and early-stage investor focused on technology and life sciences. Closest analog to BioAdvance in mission, regional mandate, evergreen orientation, and stage focus; co-invests with BioAdvance in multiple portfolio companies (e.g., Latus Bio).
  • Broadview Ventures: Boston-based early-stage life sciences venture fund focused on cardiovascular and CNS therapeutics. Directly comparable in stage (seed/Series A), sector focus, and evergreen/patient-capital orientation; Rick Jones of BioAdvance's team previously served as a Director there.

Regional players

  • BioEnterprise: Midwest (Cleveland) regional life science commercialization organization and investor in therapeutics, medical devices, and diagnostics. Comparable as a regional life science investor focused on company formation and seed-stage capital, though operating in a different geography.
  • Life Sciences Greenhouse of Central PA: Pennsylvania-focused life science seed fund with a similar mission of supporting early-stage companies within the state. Comparable regional mandate and stage focus, though narrower geographic scope within PA.
  • Robin Hood Ventures: Philadelphia-area angel investing group that focuses on early-stage companies in the Mid-Atlantic. Gregory Harriman of BioAdvance is a member; comparable in regional focus and stage, though broader sector mandate.

Broad incumbents

  • Mass General Brigham Ventures: Hospital-system-affiliated venture arm investing in therapeutics, medtech, and digital health. Comparable in sector focus and mission-driven orientation, though anchored to a single health system and broader portfolio scope than BioAdvance.
  • ARCH Venture Partners: Large, established life science venture firm investing across stages from formation to public company. Operates broadly in BioAdvance's core therapeutic verticals but at much larger check sizes and without a regional mandate.
  • Atlas Venture: Boston-based early-stage life sciences venture firm with a similar focus on building biotechs from inception. Comparable in stage and therapeutic orientation, but operates nationally and globally with substantially more capital.
  • New Enterprise Associates (NEA): One of the largest U.S. venture firms with a dedicated healthcare practice investing across therapeutics, medical devices, and digital health at all stages. Operates broadly in BioAdvance's core verticals and increasingly at seed/Series A where BioAdvance competes.

Emerging players

  • Cedars-Sinai Accelerator: Hospital-affiliated accelerator investing in early-stage health technology and digital health companies. Comparable in seed-stage health-tech orientation and ecosystem-driven model, though focused on a single health system in Los Angeles.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioAdvance social profiles

Digital presence

BioAdvance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioAdvance leadership team

Management profile

Number of profiles

Profiles18 records

BioAdvance funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioAdvance M&A and investment

M&A and investment

M&A

Investments190 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAdvance

What does BioAdvance do?

BioAdvance is a privately held, evergreen venture capital fund that invests $500,000–$1,500,000 in seed and Series A rounds (with reserves up to $5,000,000 per company over its lifecycle) in early-stage life sciences companies headquartered in the Mid-Atlantic U.S. (I-95 corridor from NYC to DC). The fund deploys capital across five sector tracks — Therapeutics, Medical Devices, Digital Health, Diagnostics, and Research Tools — and provides operational support, board participation, and introductions to follow-on investors alongside its core equity investment.

Is BioAdvance a public or private company?

BioAdvance is a private company. It is classified as unknown and is currently operating.

When was BioAdvance founded?

BioAdvance was founded in 2002. It employs 51 to 100 people.

Where is BioAdvance based?

BioAdvance is headquartered in Philadelphia, United States, in the North America region.

How does BioAdvance make money?

One revenue line is on record: investment returns from portfolio exits (evergreen fund model).

Who are BioAdvance's main competitors?

Direct peers on record are Ben Franklin Technology Partners and Broadview Ventures. Regional players are BioEnterprise, Life Sciences Greenhouse of Central PA and Robin Hood Ventures. Broad incumbents are Mass General Brigham Ventures, ARCH Venture Partners, Atlas Venture and New Enterprise Associates (NEA). Cedars-Sinai Accelerator is listed as an emerging player.

Does BioAdvance have an API?

No public API is recorded for BioAdvance.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireBioAdvance Capital Advances Life Sciences Innovation with New Investments and Portfolio MomentumBioAdvance Capital reported on its investment activities and portfolio progress for the period ending June 30, 2026, highlighting new investments in five life sciences companies and successful exits of five portfolio entities. The fund deployed capital into firms such as Agnos Bio and Ajaya Bio while realizing liquidity events through acquisitions by Waters Corporation, Natus Sensory, Insmed, Preventative Healthcare Solutions, and Elsevier. Despite a constrained early-stage funding environment, the firm maintained a disciplined approach to supporting mid-Atlantic biotech innovation.EIN PresswireBioAdvance Capital Advances Life Sciences Innovation with New Investments and Portfolio MomentumBioAdvance Capital, an evergreen fund investing in early-stage life sciences companies across the Mid-Atlantic region, reported its investment activity for the 18-month period ended June 2026, adding five new companies to its portfolio (Agnos Bio, Ajaya Bio, Atalan Tech, Ladder Bio, and Masterswitch Bio) while continuing to support 11 existing portfolio companies. The firm also recorded five exit transactions through acquisitions of portfolio companies including Halo Labs (by Waters Corporation), Keriton (by Natus Sensory), Opsidio (by Insmed), WellTrackONE (by Preventative Healthcare Solutions), and Wellsheet (by Elsevier). Despite noting continued challenges in the early-stage funding environment including protracted fundraising timelines and increased investor emphasis on capital efficiency and clinical validation, BioAdvance expressed optimism about improving capital market conditions supporting the next wave of company formation in cell and gene therapy.FinSMEsLatus Bio Raises $43M in Series A FundingLatus Bio raised $43M in Series A extension funding led by 8VC, with participation from existing and new investors. The funds will support operations and initial clinical data from its Huntington's disease and CLN2 disease programs. The company previously raised $54M in 2024.Venture Capital Access OnlineLatus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger PopulationsLatus Bio closed a $97 million Series A financing led by 8VC to advance its gene therapy pipeline. Proceeds will fund operations through key milestones, including initial clinical data from LTS-201 for Huntington's disease and LTS-101 for CLN2 disease. LTS-201 is on track for IND submission in 3Q 2026.WellsheetWellsheet Raises Series A FundingWellsheet Inc., a healthcare technology company providing AI-powered Electronic Health Record workflow solutions, announced the completion of a $3.8 million Series A funding round led by SpringTide Investments, with participation from BioAdvance and Newark Venture Partners, bringing total funding to date to $6 million. The company also appointed Dr. John Glaser and Dr. Georgia Papathomas, both veteran healthcare technology executives, to its Board of Directors. Wellsheet plans to use the proceeds to expand its engineering and go-to-market teams and extend its platform for cross-platform offerings.Venture Capital Access OnlineWellsheet Raises Series A Funding for Healthcare Workflow Platform to Reduce Time in the EHR and Physician BurnoutWellsheet Inc. announced a $3.8 million Series A funding round led by SpringTide Investments, with participation from BioAdvance and Newark Venture Partners. The company plans to utilize the capital to expand its engineering and go-to-market teams while extending its AI-powered platform designed to optimize Electronic Health Record (EHR) workflows for health systems.VatorNewsPoint-of-care diagnostic company Senzo raises $1.9MPoint-of-care diagnostic company Senzo Health raised $1.9 million in funding led by existing investors BioAdvance and Wellness Coaches, bringing its total capital to $7.7 million. The investment will support clinical trials, FDA EUA authorization, and manufacturing scale-up for its ALF COVID-19 test, with commercial availability anticipated in the second half of 2023. Senzo plans to expand its platform to detect other infectious diseases including influenza, RSV, tuberculosis, HIV, hepatitis C, and strep.PR NewswireBioAdvance Breaks Life Sciences Investing Record Year in 2022BioAdvance, a Mid-Atlantic life sciences venture investor, announced a record-breaking 2022 with over $4.7 million invested in eight new and several existing portfolio companies, marking the highest investment amount in 10 years. The record is attributed to a revamped investment strategy targeting very early-stage innovators across digital health, cell therapy, and other life sciences segments. BioAdvance's portfolio companies have collectively leveraged $3.8 billion in subsequent capital, with eleven products receiving FDA approval since 2003.PR NewswireVESTECK, Inc. Closes $5.95 M Series A Preferred equity roundVESTECK, Inc. announced the final closing of a $5.95M Series A preferred equity financing round, exceeding its original $3.5M target, with participation from New World Angels, DeepWork Capital, Ocean Azul Partners, and several Philadelphia-area investors including Ben Franklin Technology Partners, BioAdvance, Robinhood Ventures, and Angel Star Ventures. The funds will support manufacturing, pre-clinical testing, in-human procedures, and a clinical study for FDA clearance of the company's Suture-Tight nitinol suture delivery catheter for endovascular aortic aneurysm repair. VESTECK projects its technology will address an aortic repair market projected to exceed $4.5B by 2028.